Daré Bioscience, Inc.
DARE
$1.85
$0.000.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,709.59% | -94.48% | -194.64% | 173.12% | -103.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,709.59% | -94.48% | -194.64% | 173.12% | -103.52% |
| Cost of Revenue | 3,941.56% | -- | -- | -31.65% | -100.04% |
| Gross Profit | 1,399.82% | -94.48% | -194.64% | 32.22% | 99.72% |
| SG&A Expenses | -20.99% | 22.43% | -2.87% | -13.53% | -32.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -53.14% | -22.20% | -48.43% | -23.63% | -21.46% |
| Operating Income | 72.69% | 21.56% | 47.99% | 23.93% | -8.38% |
| Income Before Tax | 73.82% | 24.24% | -131.11% | 35.19% | -8.87% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 73.82% | 24.24% | -131.11% | 35.19% | -8.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 73.82% | 24.24% | -131.11% | 35.19% | -8.87% |
| EBIT | 72.69% | 21.56% | 47.99% | 23.93% | -8.38% |
| EBITDA | 82.59% | 31.71% | 54.14% | 26.43% | -8.47% |
| EPS Basic | 85.30% | 49.31% | -129.50% | 38.02% | 0.95% |
| Normalized Basic EPS | 85.30% | 49.30% | -129.50% | 38.03% | -3.15% |
| EPS Diluted | 70.69% | 49.18% | -129.79% | 38.02% | 1.06% |
| Normalized Diluted EPS | 85.30% | 49.30% | -129.73% | 38.03% | -3.15% |
| Average Basic Shares Outstanding | 78.14% | 49.46% | 5.47% | 4.57% | 9.92% |
| Average Diluted Shares Outstanding | 78.14% | 49.46% | 4.66% | 4.57% | 9.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |